For the Inventor, By the Inventor

Enter assignee name

Bengaluru, India

Sami-Sabinsa Group Limited

USPTO Granted Patents = 15

EPO Patents = 16

Forward Citations = 1

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Kalyanam Nagabhushanam (15 out of 97 patents)

Muhammed Majeed (9 out of 117 patents)

Muhammed Majeed (6 out of 9 patents)

4. Lakshmi Mundkur (5 out of 17 patents)

5. Sarang Bani (4 out of 14 patents)

6. Anjali Pandey (4 out of 16 patents)

7. Sivakumar Arumugam (4 out of 26 patents)

8. Shaheen Majeed (3 out of 15 patents)

9. Kirankumar Beede (3 out of 5 patents)

10. Furqan Ali (2 out of 24 patents)

11. Rajendran Ramanujam (2 out of 13 patents)

12. Nooruddin Thajuddin (1 out of 1 patent)

13. Krishnamurthy Kulithalai Viswanathan (1 out of 1 patent)

14. Samuel Thomas Manoharan (1 out of 1 patent)

15. John Adams Sebastian (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12465585 - Compositions for the management of seizure induced neurotoxicity (2025-11-11),

2. 12257274 - Fructophilic lactic acid producing bacteria (2025-03-25),

3. 12233032 - Compositions for management of polycystic ovary syndrome (2025-02-25),

4. 12053500 - Compositions for management of acute nephrotoxicity (2024-08-06),

5. 11957728 - Compositions for targeting receptor for advanced glycation end-products (RAGE) in a chronic inflammatory condition (2024-04-16),

6. 11925606 - Compositions for managing chronic obstructive pulmonary disease (2024-03-12),

7. 11744807 - Therapeutic compositions and methods for pulmonary fibrosis (2023-09-05),

8. 11707438 - Curcuminoid composition for therapeutic management of metabolic syndrome (2023-07-25),

9. 11491119 - Curcuminoid composition and its therapeutic potential in managing lung fibrosis (2022-11-08),

10. 11419906 - Method and composition for therapeutic management of gluten intolerance (2022-08-23),

11. 11413318 - Compositions and methods for management of atrophic gastritis and colitis (2022-08-16),

12. 11351102 - Plant actives and their anti-pollution effects thereof (2022-06-07),

13. 11299706 - Microbial bioconversion of curcuminoids to calebin-A (2022-04-12),

14. 11202810 - Stable probiotic composition for the management of lactose intolerance (2021-12-21),

15. 10959980 - Bioactive molecules from oroxylum indicum and their therapeutic applications (2021-03-30),

Company Overview

Sami-Sabinsa Group Limited is a prominent player in the field of herbal extracts and nutraceuticals, specializing in the development and manufacturing of high-quality ingredients for the pharmaceutical, dietary supplement, and food industries. The company is recognized for its commitment to research and innovation, focusing on natural products and their applications in health and wellness. Headquartered in Bengaluru, India, Sami-Sabinsa operates globally, leveraging advanced technology to enhance product efficacy and safety.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

15 Patents

#24 in Bengaluru

#126 in India

#39,881 in the World

Bengaluru, India

Sami-Sabinsa Group Limited

Forward Citations = 1

20 inventors:

Kalyanam Nagabhushanam (15 out of 97 patents)

Muhammed Majeed (9 out of 117 patents)

Muhammed Majeed (6 out of 9 patents)

4. Lakshmi Mundkur (5 out of 17 patents)

5. Sarang Bani (4 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sami-Sabinsa Group Limited. Retrieved from https://idiyas.com/company/sami-sabinsa-group

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…